Prospective Assessment of No Evidence of Disease Activity-4 Status in Early Disease Stages of Multiple Sclerosis in Routine Clinical Practice

Carlos Guevara, Cristian Garrido , Melissa Martinez , Gonzalo A. Farias , Patricia Orellana , Wendy Soruco , Pablo Alarcón , Violeta Diaz, Carlos Silva, Matthew Kempton, Gareth John Barker, José de Grazia

Research output: Contribution to journalArticlepeer-review

15 Citations (Scopus)
48 Downloads (Pure)

Abstract

Background: In relapsing-remitting multiple sclerosis, no evidence of disease activity-3 (NEDA-3) is defined as no relapses, no disability progression and no MRI activity. NEDA-4 status is defined as meeting all NEDA-3 criteria plus having an annualized brain volume loss (a-BVL) of ≤0.4%. Prospective real-world studies presenting data on NEDA-4 are scarce.
Objective: To determine the proportion of patients failing to meet one or more NEDA-4 criteria and the contribution of each component to this failure.Methods: Forty-eight patients were followed for 12 months. Structural image evaluation, using normalization, of atrophy was used to assess a-BVL.
Results: The patients had a mean age of 33.0 years (range 18–57), disease duration of 1.7 years (0.4–4) and Expanded Disability Status Scale score of 1.3 (0–4); 71% were women. All patients were on disease-modifying therapies. During follow-up, 21% of the patients had at least one relapse, 21% had disability progression, 8% had new T2 lesions, and 10% had gadolinium-enhanced lesions. Fifty-eight percent (28/48) achieved NEDA-3 status. a-BVL of >0.4% was observed in 52% (25/48). Only 29% (14/48) achieved NEDA-4 status.
Conclusion: a-BVL is a good marker to detect subclinical disease activity. a-BVL is parameter to continue investigating for guiding clinical practice in relapsing-remitting multiple sclerosis.
Original languageEnglish
Article number788
Number of pages8
JournalFrontiers in Neurology
Volume10
Issue numberJUL
DOIs
Publication statusPublished - 24 Jul 2019

Keywords

  • Brain atrophy
  • Multiple sclerosis
  • Outcome measurement (NEDA-4)
  • Quantitative MRI
  • Relapsing/remitting

Fingerprint

Dive into the research topics of 'Prospective Assessment of No Evidence of Disease Activity-4 Status in Early Disease Stages of Multiple Sclerosis in Routine Clinical Practice'. Together they form a unique fingerprint.

Cite this